Microscopic polyangiitis is an autoimmune small-vessel vasculitis that often manifests as focal and necrotizing glomerulonephritis and renal failure. Antineutrophil cytoplasmic Abs (ANCAs) specific for myeloperoxidase (MPO) play a role in this disease, but the role of autoreactive MPO-specific CD4 + T cells is uncertain. By screening overlapping peptides of 20 amino acids spanning the MPO molecule, we identified an immunodominant MPO CD4 + T-cell epitope (MPO [409][410][411][412][413][414][415][416][417][418][419][420][421][422][423][424][425][426][427][428] 
Microscopic polyangiitis is an autoimmune small-vessel vasculitis that often manifests as focal and necrotizing glomerulonephritis and renal failure. Antineutrophil cytoplasmic Abs (ANCAs) specific for myeloperoxidase (MPO) play a role in this disease, but the role of autoreactive MPO-specific CD4 + T cells is uncertain. By screening overlapping peptides of 20 amino acids spanning the MPO molecule, we identified an immunodominant MPO CD4 + T-cell epitope (MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] ). Immunizing C57BL/6 mice with MPO 409-428 induced focal necrotizing glomerulonephritis similar to that seen after whole MPO immunization, when MPO was deposited in glomeruli.
Transfer of an MPO 409-428 -specific CD4 + T-cell clone to Rag1
−/− mice induced focal necrotizing glomerulonephritis when glomerular MPO deposition was induced either by passive transfer of MPO-ANCA and LPS or by planting MPO 409-428 conjugated to a murine antiglomerular basement membrane mAb. MPO 409-428 also induced biologically active anti-MPO Abs in mice. The MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] epitope has a minimum immunogenic core region of 11 amino acids, MPO [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] , with several critical residues. ANCA-activated neutrophils not only induce injury but lodged the autoantigen MPO in glomeruli, allowing autoreactive anti-MPO CD4 + cells to induce delayed type hypersensitivity-like necrotizing glomerular lesions. These studies identify an immunodominant MPO T-cell epitope and redefine how effector responses can induce injury in MPO-ANCA-associated microscopic polyangiitis.
autoimmunity | lymphocytes | T helper 1 cells | macrophages S mall-vessel vasculitis is often induced by autoimmunity to neutrophil granule proteins, predominantly myeloperoxidase (MPO) and proteinase 3 (Pr3) (1) , as well as lysosomal membrane protein-2 (2). Although there is some overlap, autoimmunity to MPO is strongly associated with microscopic polyangiitis and reactivity to Pr3 results in granulomatosis with polyangiitis (GPA). The kidneys are frequently affected by focal and segmental necrotizing glomerulonephritis (FNGN), leading to rapidly progressive glomerulonephritis and end-stage renal failure. Due to the presence of auto-Abs to MPO and Pr3, this disease is also known as antineutrophil cytoplasmic Ab (ANCA)-associated vasculitis (3) . Morbidity and mortality rates remain high, with a 5-y survival rate of 46-85% in microscopic polyangiitis (4) , and most treatments have limited effectiveness and significant toxicities (5) .
Evidence for a pathogenic role for ANCA in microscopic polyangiitis includes the use of plasma exchange as therapy, a case report of lung hemorrhage in a neonate following placental transfer of MPO-ANCA, and other observations in humans (6, 7) . Moreover, ANCA can activate neutrophils and promote their adhesion in vitro (8) and in vivo (9) (10) (11) (12) . The adhesion of neutrophils in target tissues, particularly the kidney, induces injury by means of the release of injurious oxidants and enzymes, including MPO itself (13) . In addition, transferred anti-MPO Abs can induce neutrophil-and complement-mediated FNGN (14) (15) (16) (17) (18) , enhanced by infection-related signals like LPS (14, 19, 20) .
Although there is a rationale for autoreactive CD4 + cells contributing to the development of disease in microscopic polyangiitis, their role is less clear. There is evidence that MPO-ANCA production requires antigen-specific CD4 + T cells (21, 22) . Furthermore, autoreactive MPO-specific CD4 + T cells can be induced experimentally in animals (23) , MPO-specific T cells that produce IFN-γ are present in the peripheral blood of humans with acute ANCA-associated vasculitis (24) (25) (26) , and urinary CD4 + effector/memory cells reflect disease activity (27) . Effector/memory CD4 + T cells, together with macrophages, tissue factor, and fibrin, are present in glomeruli of patients with ANCA-associated glomerulonephritis (28, 29) . Finally, in a murine model of anti-MPO FNGN, where autoimmunity to MPO is induced and glomerulonephritis is triggered by injection of sheep anti-mouse glomerular basement membrane (GBM) Ab, CD4 + T-cell depletion during the effector phase attenuated disease (23) . Based on this evidence, we hypothesize that MPO-specific effector CD4
+ cells are important in disease by localizing to glomeruli and inducing a delayed type hypersensitivity (DTH)-like lesion. Anti-MPO CD4 + cells may localize to glomeruli by recognizing MPO within glomeruli, acting as a planted glomerular autoantigen deposited by ANCA-activated neutrophils that have degranulated and/or formed neutrophil extracellular traps (NETs) (30) .
Although MPO's B-cell epitopes have been the subject of studies mapping them to areas within the heavy chain (31, 32) , the T-cell epitopes of MPO are undefined. Identifying MPO's Tcell epitopes is important in understanding the pathogenesis of anti-MPO disease and would represent progress toward less toxic therapies focused on the autoimmune response. In the current studies, we have defined an immunodominant CD4 + T-cell MPO epitope and then used this epitope to test the hypothesis that antigen-specific CD4 + T cells recognize both this epitope and MPO itself in glomeruli and induce FNGN. This immunodominant T-cell epitope exists across at least three different MHC II alleles and also can induce MPO-ANCA. Our studies redefine our understanding of anti-MPO disease to now include a distinct role for effector CD4 + T cells that recognize MPO, which are planted in glomerular capillaries by MPO-ANCA-activated neutrophils. The pathogenesis of effector responses in microscopic polyangiitis should now be considered to include a sequential mix of types II (Ab-mediated) and IV (DTH-like) hypersensitivity.
Results
MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] Is the Immunodominant T-Cell Epitope of MPO. To define CD4 + T-cell epitopes within MPO, we immunized groups of C57BL/6 mice with pools of MPO 20-mers (from the mouse MPO sequence, with each peptide overlapping by 12 aa; Table  S1 ). Separate groups of mice were injected with peptide pools from the proregion of MPO (peptides 1-17), the light chain (peptides 18-31), or one of four quarters (H1-H4) of the heavy chain (peptides 32-46, 47-61, 62-76, or 77-89). Splenocytes were restimulated with each third of the relevant immunizing pool (e.g., splenocytes from the group immunized with peptides 1-17 were restimulated with peptides 1-6, 7-12, or [13] [14] [15] [16] [17] , and recall responses were measured by IFN-γ enzyme-linked immunospot (ELISPOT) assay. The five peptide groups inducing the strongest responses were peptide pools 7-12, 23-27, 52-56, 57-61, and 62-66 (Fig. 1A) . Additional groups of mice were then immunized with one of these groups of peptides, and their draining lymph node (LN) cells were restimulated with each of the individual peptides from within the immunizing pool. The five individual peptides that induced the strongest recall responses were peptides 10, 24, 52, 57, and 61 (Fig. 1B) . To determine the immunodominant MPO T-cell epitope, we then immunized separate groups of mice with each of these peptides and restimulated their draining LN cells ex vivo with either the immunizing peptide or recombinant mouse MPO using proliferation assays and ELISPOT assays for IFN-γ and IL-17A. Comparing recall responses, MPO peptide 52 (MPO 409-428 , PRWNGEKLYQEARKIVGAMV) induced the strongest responses both to itself and to whole recombinant mouse MPO (Table 1) . Proliferative responses were significantly higher than those induced by all other peptides. Although proinflammatory cytokine production after peptide 52 immunization was numerically greater than after all other peptides, peptide 61 also induced moderately strong IL-17A and IFN-γ production.
Mice immunized with native mouse MPO (n = 5) developed recall responses to peptide 52 but not to a control peptide, ovalbumin (OVA) 323-339 (proliferation assay stimulation index: 2.1 ± 0.2 vs. 1.0 ± 0.1, IFN-γ ELISPOT assay: 8.0 ± 1.8 spots, and IL-17A ELISPOT assay: 10.3 ± 1.7 spots; no samples restimulated with OVA 323-339 showed any spots above media alone). Immunization with peptide 53 or 54, both of which overlap with peptide 52 and induce recall responses by IFN-γ ELISPOT assay in mice immunized in peptide pool 52-56 ( Fig. 1 A and B) , did not induce responses to peptide 52, 53, or 54 or to recombinant MPO (Fig. S1 ). (33) with the pool of MPO peptides 52-56. In both strains, peptide 52 was the immunogenic peptide ( Fig. 2 A and B) . BALB/c and HLA-DRB1*15:01 Tg mice immunized with mouse MPO peptide 52 developed autoreactive responses to both MPO peptide 52 and to whole recombinant MPO ( Fig. 2 C and D) .
Defining the Core and Critical Residues of the MPO 409-428 Epitope. We then further delineated the key areas of this T-cell epitope. We identified the critical peptide length for immunoreactivity by immunizing C57BL/6 mice with the complete 20-aa MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] (PRWNGEKLYQEARKIVGAMV) and measuring proliferative recall responses to shortened 16-mers and 12-mers of MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] (Fig. 3A ). There were no detectable recall responses when MPO 409-428 was shortened from the C terminus to either a 16-mer, amino acids 409-424, or to a 12-mer, amino acids 409-420 (Fig. 3A) . However, recall responses with amino acids 413-428, containing the 16 C-terminal amino acids, were comparable to recall responses induced by full-length amino acids 409-428. The recall response to the 12 C-terminal amino acids 417-428, although detectable, was reduced compared with MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] . To delineate the core immunoreactive residues of MPO 409-428 further, mice were immunized with the 16-mer amino acids 413-428 and recall responses to sequential 12-mers overlapping by 11 aa were measured. Restimulation of mice immunized with amino acids 413-428 with the 12-mers containing amino acids 414-425 (Fig. 3B) . Therefore, the core immunoreactive residues of MPO 409-428 are the 11 amino acids (415-425; KLYQEARKIVG). The critical residues within this 11-mer were delineated by immunizing C57BL/6 mice with KLYQEARKIVG and restimulating draining LN cells with individual alaninesubstituted 11-mers [alanine itself (MPO 420 ) was substituted by a serine]. Each 11-mer had one residue substituted by alanine in sequential order. An individual amino acid was deemed a critical residue if its substitution by an alanine abrogated a positive ex vivo proliferative response. The substitution of tyrosine, arginine, isoleucine, or valine defined these amino acids as the critical residues within this epitope (Fig. 3C ).
MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] Immunization Induces Nephritogenic T-Cell Responses. To determine the nephritogenicity of the anti-MPO T-cell responses generated by MPO 409-428 immunization, a previously established model of anti-MPO-directed glomerulonephritis was used (23, 34) . In this model, C57BL/6 mice immunized with mouse MPO lose tolerance to MPO, but this autoimmunity, in itself, is not sufficient to induce glomerulonephritis, which is triggered by injecting low-dose sheep anti-mouse GBM Ab. This Ab induces transient glomerular neutrophil recruitment with MPO deposition in glomeruli. MPO 409-428 -immunized mice developed renal injury with increased albuminuria and blood urea nitrogen to a similar degree as mice immunized with whole native mouse MPO (Fig. 4 A and B) . MPO 409-428 -immunized mice developed FNGN comparable to mice immunized with whole native mouse MPO, characterized by segmental glomerular necrosis and fibrin deposition within the glomerular tuft. Mice immunized with OVA 323-339 and given anti-GBM Ab exhibited only mild lesions (Fig. 4 C-J) . Analysis of glomerular cellular effectors showed increased infiltration of CD4 + T cells and macrophages compared with control mice, similar to that seen after whole native mouse MPO immunization (Fig. 4 K-M) . Concurrently, a group of mice (n = 6) immunized with the next highest responding MPO peptide from Groups of mice were immunized with individual peptides, and immune responses to the immunizing peptide or to whole recombinant mouse MPO were measured ex vivo using an [ 3 H]-thymidine proliferation assay and IFN-γ and IL-17A ELISPOT assays. SI, stimulation index; spots, mean number of spots minus baseline. Results are presented as the mean ± SEM and are representative of three independent experiments, each with a minimum of five mice per group. *P < 0.05 vs. peptides 10, 24, 57, and 61; **P < 0.05 vs. peptides 10, 24, and 57; ***P < 0.05 vs. peptides 10 and 24. Mice receiving the MPO 409-428 -specific T-cell clone developed progressive FNGN with increased albuminuria, blood urea nitrogen, segmental glomerular necrosis, and fibrin deposition compared with mice that received OVA 323-339 -specific T cells and anti-GBM Ab (Fig. 5 A-F ). There were increased CD4 + T cells and macrophages, but not neutrophils, within glomeruli compared with control clone recipients (Fig. 5 I-K) . The degree of perivascular and tubulointerstitial inflammation was also increased, with more CD4 + T cells and macrophages but similar numbers of neutrophils in the tubulointerstitium ( Fig. S2 and Table S2 ). Glomerular crescent formation was observed in mice receiving the MPO 409-428 -specific T-cell clone at day 14 (6 ± 2% of glomeruli affected) but not in mice receiving OVA 323-339 -specific T cells. In some mice, pulmonary histology showed signs of interstitial pneumonitis and lymphocytic bronchiolitis, but these findings were inconsistent and not present in all clone transfer studies.
Localizing MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] to Glomeruli Induces CD4 + T-Cell CloneMediated FNGN. To determine whether the presence of the T-cell epitope MPO 409-428 itself in glomeruli can induce T-cellmediated renal injury in mice with MPO 409-428 CD4 + T cells, we injected a biotinylated MPO 409-428 peptide conjugated to a mouse anti-mouse monoclonal IgG1 (clone 8D1) specific for the mouse noncollagenous domain of the α3 chain of type IV collagen, which does not induce pathological albuminuria or major histological changes (35) . Glomerular deposition of biotinylated MPO 409-428 was demonstrated by direct immunofluorescence using streptavidin-FITC Ab ( Fig. 6 H-K). Glomerular crescent formation was observed in four of six mice receiving the MPO 409-428 -specific clone (3%, 5%, 5%, and 10% of glomeruli affected) but not in mice receiving OVA 323-339 -specific cells. These pathological abnormalities translated into functional injury with increased albuminuria and blood urea nitrogen levels ( Fig. 6 L and M) . Similarly, perivascular inflammation, tubulointerstitial injury, and infiltration of effector cells were observed in mice that received the MPO 409-428 -specific clone (Table S2) . These experiments show that MPO 409-428 itself in glomeruli, without the initial presence of neutrophils or endogenous MPO, is sufficient to induce effector MPO-specific T-cell localization and injury.
LPS and MPO-ANCA Recruit Neutrophils and Deposit MPO, Leading to CD4 + T-Cell-Mediated FNGN. Relapse of ANCA-associated vasculitis is associated with infections (36, 37) . At least part of the explanation for these clinical observations may come from experimental evidence showing that infection primes neutrophils [and potentially other cells (20) ], allowing ANCA to bind to and activate neutrophils (9, 19) . This results in their recruitment to target tissues, especially the kidney (9, 15) . Modeling this process involves injecting LPS and transferring anti-MPO IgG (generated in Mpo −/− mice) into mice. Although these Abs can induce injury (14) , recruiting neutrophils into glomeruli may also result in the deposition of MPO within glomeruli, where effector CD4 + cells could potentially recognize MPO as a planted glomerular antigen. Having shown that MPO-specific CD4 + cells can recognize the immunodominant MPO T-cell epitope, MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] , in the glomerulus, we next tested the hypothesis that MPO from anti-MPO Ab-activated neutrophils acts as an autoantigen in target tissues, resulting in effector CD4 + cell-mediated injury. Mice were injected with LPS and anti-MPO IgG (generated by immunizing Mpo −/− mice with murine MPO). Histological analyses 3 h after injection showed [as previously demonstrated (20) ] glomerular neutrophil recruitment after LPS and anti-MPO IgG (Fig. 7 A, C, and D) . There was also increased renal [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] (underlined) because both induced comparable reactivity to the immunizing MPO [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] . (C) To determine the critical residues, mice were immunized with the core 11 amino acids, MPO [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] , and draining LN cells were restimulated ex vivo with alanine-substituted 11-mers. Alanine-substituted positions: +, MPO 415-425 ; K, ALYQEARKIVG; L, KAYQEARKIVG; Y, KLAQEARKIVG; Q, KLYAEARKIVG; E, KLYQAARKIVG; A, KLYQESRKIVG; R, KLYQEAAKIVG; second K, KLYQEARAIVG; I, KLYQEARKAVG; V, KLYQEARKIAG; G, KLY-QEARKIVA; −, OVA 323-339 ; MPO, whole recombinant mouse MPO. Reactivity to individual alanine-substituted 11-mers was compared with reactivity to MPO [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] and showed that tyrosine (Y), arginine (R), isoleucine (I), and valine (V) were critical to the response. *P < 0.05; ***P < 0.001. Results are representative of two independent experiments, each with a minimum of four mice per group. Each dot represents the mean response from an individual mouse. SI, stimulation index.
MPO activity (Fig. 7B) . Confocal microscopy using anti-CD45 and MPO-specific Abs revealed the presence of leukocyte-associated MPO as well as extracellular MPO that had been deposited in the glomerulus (Fig. 7E) .
Injecting LPS and anti-MPO Abs after transferring either 5 × 10 6 or 25 × 10 6 MPO 409-428 -specific CD4 + T-cell clones induced significant renal disease compared with transfer of LPS and OVA 323-399 -specific cells. MPO-specific effector T cells resulted in increased albuminuria, blood urea nitrogen, and FNGN with glomerular necrosis and fibrin deposition (Fig. 7 F-M) . Renal injury was more severe after 25 × 10 6 MPO-specific cells compared with 5 × 10 6 MPO-specific cells. Glomerular crescent formation was observed in three of six mice that received 25 × 10 6 MPO-specific cells (with 10%, 15%, and 45% of glomeruli affected) but not in mice receiving 5 × 10 6 MPO-specific cells. There were also increases in glomerular infiltration of CD4 + T cells, macrophages, and neutrophils, similar to those observed when using the MPO 409-428 -8D1 conjugate to plant the T-cell epitope in glomeruli (Fig. 7 N-P) . Perivascular and tubulointerstitial injury followed a similar pattern (Table S2 ). Transfer of 50 × 10 6 MPO 409-428 -specific cells resulted in markedly accelerated renal disease specific to mice receiving MPO-specific cells, and experiments were terminated at 6 d (Fig. S3 ).
MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] Induces Biologically Active MPO-ANCA. Indirect immunofluorescence using purified IgG on ethanol-fixed peritoneal mouse neutrophils showed a p-ANCA pattern specific to MPO 409-428 -immunized mice and not seen in serum IgG from OVA 323-339 -immunized mice or when IgG from MPO 409-428 -immunized mice was applied to neutrophils from Mpo −/− mice ( Fig. 8 A-C) . To determine if immunization with MPO 409-428 induced MPO-ANCA, we tested sera from MPO 409-428 -immunized C57BL/6 mice for MPO-specific IgG by ELISA. Sera from OVA 323-339 -or whole native mouse MPO-immunized mice served as negative and positive controls. MPO 409-428 -immunized mice developed MPO-ANCA IgG, albeit at lower titers compared with whole native mouse MPO immunization (Fig. 8D) . To determine whether MPO-ANCA induced by MPO 409-428 had functional activity, we transferred purified MPO-ANCA into LPS-primed C57BL/6 recipient mice. Compared with IgG from OVA 323-339 -immunized mice, serum IgG from MPO 409-428 -immunized mice resulted in increased glomerular neutrophil recruitment at 3 h, (Fig.  8E) , showing that these auto-Abs are biologically active.
Discussion
The glomerulus is a common target in MPO-ANCA-associated microscopic polyangiitis, with the severity of renal disease often defining the outcome. Although ANCA-and neutrophil-induced injury is important in microscopic polyangiitis, the presence of CD4 + T cells (26) + T cells (K) and macrophages (L) but not neutrophils (M) were increased after MPO 409-428 immunization. gcs, glomerular cross section. *P < 0.05; **P < 0.01; ***P < 0.001.
specific CD4
+ T cells provide T-cell help to autoreactive B cells in producing MPO-ANCA. In many people who develop MPO-ANCA, these auto-Abs interact with and activate neutrophils, causing the neutrophils to be recruited to glomerular capillaries. Neutrophils mediate injury but, critically, also release the autoantigen MPO, which then is present in glomeruli and can be recognized by autoreactive MPO-specific CD4 + cells. Glomerular localization of these damaging MPO-specific effector T cells results in the recruitment of effector leukocytes, the development of FNGN, and renal impairment.
In contrast to other autoimmune diseases, there have been no consistent MHC class II associations in microscopic polyangiitis. HLA typing studies in patients with ANCA-associated vasculitis have focused largely on GPA (most frequently marked by autoimmunity to Pr3). In this disease, a variety of MHC class II associations have been found (reviewed in 38), with DPB1*04:01 being the most consistent. There are, however no clear positive associations with microscopic polyangiitis, which usually features autoimmunity to MPO with MPO-ANCA. We therefore tested the immunogenicity of MPO 409-428 in mice with I-A d and mice with HLA-DRB1*15:01, finding that this peptide could induce immune responses in more than one MHC II haplotype. Further studies in C57BL/6 mice identified a minimum immunogenic peptide, MPO [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] , and several critical amino acids within this peptide.
When glomerular disease was triggered with low-dose anti-GBM Ab, MPO 409-428 peptide-immunized mice (but not OVA 323-339 -immunized mice) developed significant FNGN, showing that immunity to this peptide induced FNGN. MPO is a major constituent of neutrophils and is released when neutrophils induce inflammation, contributing to tissue injury by generating damaging oxidants (13, 39) . However, in microscopic polyangiitis following ANCA-induced glomerular neutrophil localization, neutrophils release MPO that is deposited in glomeruli (28, 30) . Immunologically, the glomerulus becomes a site where MPO, the autoantigen, is present and available for antigen recognition by effector T cells.
Therefore, after generating T helper (Th) 1 IFN-γ-secreting MPO 409-428 -specific clones that induced dermal DTH in vivo, we performed a series of transfer experiments demonstrating that MPO-specific CD4 + cells induce FNGN after MPO has been deposited in the glomerular microvasculature. This antigenspecific disease (not found in recipients of OVA-specific CD4 + T cells) was characterized by segmental glomerular necrosis; glomerular fibrin deposition; CD4 + T-cell, macrophage, and neutrophil recruitment; and functional renal injury (albuminuria and raised blood urea nitrogen). Tubulointerstitial infiltrates and injury, in the form of tubular dilation, necrosis, and protein cast formation, as well as perivascular inflammation were present in mice receiving MPO-specific CD4 + cells. Because injection of anti-GBM Ab induces neutrophil recruitment, increased renal MPO activity, and free MPO within the glomerulus, we initially injected these Abs to trigger disease (34, (39) (40) (41) . However, this strategy of inducing glomerular MPO deposition is confounded by anti-GBM Ab-induced neutrophil recruitment and the enzymatic effects of MPO, which, together, complicate the study of MPO as an autoantigen. By defining an immunodominant MPO peptide, we have defined a role for MPO as a planted autoantigen distinct from its effects as an injurious effector molecule. To determine whether MPO 409-428 itself could be recognized as a nephritogenic peptide within glomeruli, we used a modification of our previously published delivery system (35) . By conjugating MPO 409-428 to a nonimmunogenic mouse anti-mouse GBM monoclonal IgG1 Ab, we could plant MPO 409-428 in glomeruli. Compared with some other murine IgG subclasses, the murine IgG1 subclass has limited capacity to cause injury itself, because it fixes complement poorly and has a relatively low affinity for leukocyte-activating Fcγ + T cells (G) and macrophages (H) but not neutrophils (I) over time were seen in recipients of MPO-specific T cells. gcs, glomerular cross section. *P < 0.05; **P < 0.01; ***P < 0.001.
receptors (42) . At the dose that we used, the Ab itself induces minimal leukocyte recruitment and no albuminuria (35) . Therefore, compared with polyclonal sheep IgG or anti-MPO Abs, it served as a relatively inactive carrier that could localize MPO 409-428 to glomeruli. When effector CD4 + cells were transferred into mice, only MPO-specific cells localized to glomeruli and induced significant FNGN with renal impairment.
Studies in patients with ANCA-associated vasculitis show associations between infection and disease relapse and activity, suggesting a role for infection in the pathogenesis of these diseases (36, 37) . Having shown that MPO-specific T cells could recognize MPO 409-428 within glomeruli to induce injury, we triggered disease with transferred anti-MPO Abs and LPS, a prototypic infection-related signal. This is likely to be more analogous to the "clinical" situation, where enzymatically active and autoantigenic MPO lodges in glomeruli when it is released by MPO-ANCA-activated neutrophils. LPS has activating effects on both neutrophils and intrinsic glomerular cells, including induction of the production of neutrophil chemoattractants by glomerular endothelial cells (20) . Although, as expected, there was some relatively mild injury induced by the initial LPS and anti-MPO Ab-induced glomerular neutrophil recruitment, MPO-specific T cells caused significant and dose-dependent FNGN, with the highest dose of cells resulting in rapidly progressive renal failure in an antigen-specific manner and premature termination of experiments. These experiments show that the humoral and cellular arms of the autoimmune response to MPO collaborate to induce ANCA-associated vasculitis.
There are several ways by which MPO, an abundant protein in neutrophils, can become lodged in glomeruli in ANCA-associated glomerulonephritis. Although ANCA-induced neutrophil recruitment results in neutrophil degranulation, ANCA also promotes NET formation (30) . These NETs are extracellular, include both MPO and Pr3, and are present in glomeruli in ANCA-associated glomerulonephritis. In addition, neutrophil microparticles, which are present in ANCA-associated vasculitis, contain MPO and can localize to endothelial cells (43) . It remains to be determined which cell type presents MPO 409-428 to effector CD4 + cells in glomeruli, allowing antigen-specific local MPO recognition. Leukocytes traditionally present antigens to effector CD4 + cells. Dendritic cells (rare in glomeruli) or monocyte/macrophages may be important in ingesting MPO present within glomeruli to allow glomerular T-cell recognition of antigen, whereas neutrophils themselves can also express MHC II and present antigens under some circumstances (44) . Alternatively, intrinsic glomerular cells could be important, because they can both internalize MPO (45) and be in contact with intracapillary MPO-specific CD4 + T cells. Studies in murine glomerulonephritis induced by a planted foreign antigen support a role for glomerular cells in both antigen recognition and activation of effector CD4 + cells (46) (47) (48) . Chimeric mice lacking MHC II expression (46) or the costimulatory molecule CD40 (47) in renal tissue cells did not develop severe T cell-mediated glomerulonephritis, and in the same model, glomerular CD80 and CD86 contributed to injury (48) . Both effector Th1 cells and Th17 cells are important in experimental glomerulonephritis induced by a planted foreign antigen (35, (49) (50) (51) , whereas in autoimmune diseases, cell-mediated injury can be mediated by either Th1 cells, Th17 cells, or both Th1 and Th17 cells (52) (53) (54) . We have shown that either Th1 cells or Th17 cells can induce injury in glomerulonephritis (35), and evidence exists for the involvement of both Th1 and Th17 cells in human immune renal injury (55, 56) . Although some human observational studies and our recent experimental data support a role for Th17 cells and IL-17A in ANCA-associated glomerulonephritis (34, 57, 58) , other studies implicate Th1 cells (59) . The current studies, in showing that injury can be mediated + cells (N) and antigen-specific increases in macrophages (O) and neutrophils (P). gcs, glomerular cross section. *P < 0.05; **P < 0.01; ***P < 0.001.
by IFN-γ-secreting Th1 cells, support a model wherein both Th1 and Th17 cells mediate injury in anti-MPO disease.
The MPO 409-428 epitope can also induce MPO-ANCA with some biological activity, because transfer of pooled IgG from MPO 409-428 -immunized mice with LPS could induce modest glomerular neutrophil recruitment. The target areas for human MPO-ANCA have been identified in regions within the MPO heavy chain (MPO 387-745 , corresponding to mouse MPO 360-718 ) (31) , which include our T-cell epitope, although it is not necessary for autoreactive T-cell and B-cell epitopes to be from similar parts of the autoantigen. Targeted antigen-specific therapy is a long-term aim in treating autoimmune disease. The identification of an important epitope within MPO provides a platform for further work aimed at developing antigen-specific therapies, given the apparently relatively restricted range of autoantigens in microscopic polyangiitis with MPO-ANCA.
When considered with published data on the role of ANCA in disease, our studies demonstrate that tissue injury in microscopic polyangiitis is mediated by the following series of events. Following neutrophil priming and activation by the coordinate action of infection-related signals and MPO-ANCA, neutrophils are recruited to glomeruli. Here, they initiate injury not only by releasing injurious mediators but by depositing MPO, the autoantigen, in glomerular capillaries. The presence of MPO within these small vessels allows effector MPO-specific CD4 + T cells to localize to glomeruli and induce a DTH-like necrotizing glomerulonephritis. Therefore, the pathogenesis of microscopic polyangiitis includes distinct and important roles for both MPO-ANCA-activated neutrophils and autoreactive effector CD4 + T cells that recognize MPO within glomeruli.
Materials and Methods
MPO Peptides, Proteins, and Mice. Peptide libraries for MPO T-cell epitope screening assays were synthesized as PepSets (Mimotopes). Peptides were 20 aa long and overlapped by 12 aa. Peptide sequences are based on National Center for Biotechnology Information reference NP_034954 (mouse MPO; Table S1 ). Individual peptide immunization and restimulation assays were performed with >90% pure peptides by HPLC (Mimotopes or AusPep). OVA 323-339 was purchased from Auspep. Native mouse MPO was purified from a mouse cell line, 32Dcl3, and recombinant mouse MPO was generated using a baculovirus system, as previously described (60) . C57BL/6 and BALB/c mice were obtained from Monash Animal Services, Monash University. (20) . Injury was assessed at day 5 or at day 14 posttransfer. To conjugate MPO 409-428 to 8D1 mAb, 5 mg/mL (grown in-house) was reacted with 0.1 mg/ mL N-succinimidyl-6-maleimido-caproate (Sigma) for 2 h. MPO 409-428 (10 mg/ mL) was combined with 8D1 mAb at 10-fold molar excess for 3 h, the reaction was stopped by adding 2 mM cysteine, and unconjugated peptide was removed by dialysis in PBS. Conjugation was confirmed by Western blot using streptavidin-HRP Abs (BD Biosciences). Additional methods are detailed in SI Materials and Methods.
Statistics. Where there were three or more groups (the majority of experiments), including experiments across different time points, one-way ANOVA followed by Tukey's posttest was used to assess differences. Where there were only two groups, a Student t test was used. Means and SEMs are shown (*P < 0.05, **P < 0.01, and ***P < 0.001).
Study Approval. These studies were conducted in strict accordance with the Australian code of practice for the care and use of animals for scientific purposes by the National Health and Medical Research Council of Australia. Animal studies were approved by the Monash University Animal Ethics Committee. Assessment of Tissue Injury and Immune Cell Infiltration. Glomerular segmental necrosis and crescent formation were assessed on 3-μm-thick, PAS-stained, formalin fixed, paraffin-embedded sections (≥50 glomeruli per mouse). Glomerular necrosis was defined as accumulation of periodic acid-Schiff (PAS)-positive material in the glomerulus with hypocellularity, and a glomerular crescent was defined as two or more layers of cells in Bowman's space. Perivascular inflammation was assessed by counting the number of cell layers surrounding arteries/arterioles (in 15 consecutive vessels). Tubular injury was scored based on the presence of tubular dilation, necrosis, and protein cast formation, and a score of 1 was given for each focus of injury in a mediumpower field (×200, in ≥20 consecutive cortical fields). Fibrin deposition was assessed on 3-μm-thick paraffin-embedded sections (≥50 glomeruli per mouse) using a rabbit anti-mouse fibrinogen Ab (R-4025) with an ABC kit (DAKO) using diaminobenzidine (DAB; Sigma). Lungs were formalin-fixed and paraffin-embedded, sectioned 3 μm thick, and PAS-stained. Urine was collected 24 h before the end of experiment using metabolic cages. Urinary albumin was assessed by ELISA (Bethyl Laboratories) and expressed as milligrams per micromoles of creatinine. Urinary protein was assessed by the Bradford method. Blood urea nitrogen was measured using standard laboratory methods. CD4 + T cells, macrophages, and neutrophils were detected by immunoperoxidase staining of 6-μm-thick periodate lysine paraformaldehydefixed frozen kidney sections. The primary mAbs used were GK1.5 (anti-mouse CD4; American Type Culture Collection), FA/11 [macrophages, anti-mouse CD68; gift from Gordon L. Koch (Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom)], and RB6-8C5 (neutrophils, antiGr-1). A minimum of 20 consecutively viewed glomeruli were assessed per animal. To measure dermal delayed type hypersensitivity (DTH), mice were challenged by intradermal injection of 10 μg of recombinant mouse MPO, diluted in PBS, into the left plantar footpad. The same volume of PBS was administered into the contralateral footpad. DTH was quantified 24 h later by measurement of the difference in footpad thickness.
T-Cell Cloning. MPO 409-428 -specific CD4 + clones were generated by immunizing C57BL/6 mice s.c. with 10 μg of MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] (Mimotopes) in Freund's complete adjuvant. Draining lymph node cells were harvested after 10 d and then cultured at a concentration of 3 × 10 6 cells per well in 6-well plates with 10 μg/mL MPO 409-428 in supplemented RPMI media. Well-isolated colonies of proliferating cells were identified by light microscopy and by repeated micromanipulation, and single cells were transferred into individual wells in a 96-well plate with 10 6 splenocytes per well from naive C57BL/6 mice whose cells were CD4 + -depleted [by mouse CD4 (L3T4) MACS Microbeads with LD columns; Miltenyi] and mitomycin C-treated (5 × 10 6 cells/mL with 50 μg/ mL mitomycin C in PBS for 30 min at 37°C). Cells were cultured in supplemented RPMI media with 50 U/mL recombinant mouse IL-2 (eBioscience) and 50 μg/mL MPO 409-428 , which was changed weekly, and cell viability was assessed at 4 wk by means of [ 3 H]-thymidine proliferation assay. Viable clones were expanded in 24-well plates with weekly media changes; fortnightly division; and addition of CD4 + -depleted, mitomycin C-treated splenocytes. As a control, T cells from an immunized OT-II mouse were selected and expanded in vitro by the same method. The TCR Vβ expression was screened by FACS using the Mouse Vβ TCR Screening Panel (BD Biosciences). Vα expression was screened by FACS using anti-Vα2-, 3.2-, and 8-specific Ab (Biolegend). The MPO T-cell clone used expressed Vα3 and Vβ14 and secreted IFN-γ.
MPO Activity Assay and Detection of MPO in Glomeruli. Kidneys were weighed, homogenized in 50 mM potassium phosphate buffer (pH 6.0, 1:40 wt/vol) and incubated for 2 h; homogenates were then centrifuged (30,000 × g, 15 min), and supernatant was collected and assayed for MPO activity. Kidney extract (100 μL) was added to 1 mL of 50 mM potassium phosphate buffer (pH 6.0) with 0.167 mg/mL o-dianisidine (Sigma) and 0.0005% H 2 O 2 (Sigma), and the rate of absorbance (A 460 ) was measured. To detect MPO in glomeruli, frozen kidney sections were stained with anti-CD45 biotin (1:100), streptavidin-phycoerythrin-conjugated Ab (1:100; BD Biosciences) and FITC-conjugated anti-MPO (1:10, 8F4; Hycult Biotech). Images were captured using a Nikon C1 inverted confocal laser and Nikon Ti-E scanning microscope.
Generation, Detection, and Function of Anti-MPO Abs. C57BL/6 mice were immunized with 20 μg of MPO [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] or OVA 323-339 emulsified in Freund's complete adjuvant and boosted in Freund's incomplete adjuvant on days 7 and 14, and were culled on day 28. Serum was collected, pooled, and IgG-purified using protein G columns by FPLC. Polystyrene 96-well ELISA plates were coated with 5 μg/mL native mouse MPO or recombinant mouse MPO blocked with 200 μL per well of 2% (vol/vol) casein/ PBS, and mouse serum was added at a dilution of 1:200. MPOspecific mouse IgG was detected using HRP-conjugated antimouse IgG Ab (GE Healthcare) diluted 1:2,000. For indirect immunofluorescence, peritoneal neutrophils were harvested by peritoneal lavage using 10 mL of cold PBS from C57BL/6 or Mpo −/− mice injected i.p. with 1 mL of 3% (vol/vol) thioglycollate/ PBS. Neutrophils were cytospun onto slides and fixed in ethanol (4°C, 15 min), purified serum IgG (1 mg/mL) was applied to fixed neutrophils for 20 min, and anti-mouse IgG Ab was then detected using FITC-conjugated anti-mouse IgG Ab (Silenus). To determine whether anti-MPO Abs had functional activity, mice were primed with 10 μg of LPS in 0.5 mL of PBS 2 h before i.v. injection of 1 mg of serum IgG from MPO 409-428 -or OVA 323-339 -immunized C57BL/6 mice, and kidneys were then harvested after a further 3 h. anti-MPO Abs. Although control mice (○) survived until the end of experiments, mice receiving MPO-specific cells (•) developed severe injury; some were humanely killed early, and experiments were ended at day 6. Mice receiving MPO-specific cells developed renal failure (blood urea nitrogen from serum of mice culled after day 5, n = 4) and severe necrotizing glomerulonephritis (data on graph represent all 8 mice, including those humanely killed before day 6), whereas control mice had normal renal function and only mild glomerular disease. ***P < 0.001. 
